MDR-TB Headlines the 2009 Pacific Health Summit
Each year, the Pacific Health Summit convenes global thought leaders to better understand how to harness scientific advances to tackle
News
News
New development in TB treatment
Pharmaceutical giant Tibotec and the non-profit Global Alliance for TB Drug Development (TB Alliance) have teamed up to expedite the
News
TB Alliance, Tibotec, form partnership to take forward new drug
TB Alliance, Tibotec, form partnership to take forward new drug Keith Alcorn Wednesday, June 17, 2009 Aidsmap.com Tibotec announced today
News
J&J, nonprofit join to speed TB drug development
Healthcare company Johnson & Johnson (JNJ.N: Quote, Profile, Research, Stock Buzz) said on Wednesday it has joined with the nonprofit
News
Unique Collaboration Between TB Alliance And Tibotec to Accelerate Tuberculosis Drug Development
[Seattle, WA] A new landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance) a not-for-profit, product development
News
J&J, Tibotec team with TB Alliance to develop and give access to tuberculosis drug
NEW YORK (AP) – Drug developer Johnson & Johnson said Wednesday it will work with the Global Alliance for TB
News
TB Alliance Announces Four Drug Discovery Collaborations
The Global Alliance for TB Drug Development (TB Alliance), a not-for-profit product development partnership accelerating the discovery and development of
News
TB Alliance and DNDi Announce Collaborations with Anacor to Apply Boron Technology to Identify New Medicines for Neglected Diseases
Anacor Pharmaceuticals today announced that it has entered into a license and research agreement with the Global Alliance for TB
News
New grant supports advocacy for health technologies for the developing world
Global Health Technologies Coalition receives funding to encourage new health solutions for the developing world Washington, DC, USA, May 15,
News
NAPAMBANA NA KIFUA KIKUU, JIUNGE NAMIS SASA.
On March 24, 2009 the TB Alliance Community Engagement Program sponsored Community Advisory Boards (CABs) at four REMoxTB clinical trial